Skip to main content
TipRanks
Go Ultimate75% OFF

Purple Biotech (1YI0) Stock Price & Analysis

0 Followers

1YI0 Stock Chart & Stats

€0.28€0.00(0.00%)
At close: 5:30 PM GMT+1
€14€15€16Mar 12Jun 3
Day’s Range
EUR 0.28 - EUR 0.38
52-Week Range
EUR 0.28 - EUR 0.38
Previous Close
EUR 0.28
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 9.06M
Enterprise Value
-EUR 4.20M
Total Cash (Recent Filing)
EUR 6.11M
Total Debt (Recent Filing)
EUR 134.00K
Price to Earnings (P/E)
―
Beta
N/A
Next Earnings
Feb 10, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low leverage reduces refinancing and solvency pressure while preserving financial flexibility for clinical development. Although the company is loss-making, its limited debt burden avoids adding substantial interest obligations or mandatory repayment demands during the commercialization process.

Strengthening Oncology IP

The CAPTN-3 patent allowance strengthens protection for Purple Biotech’s modular multispecific antibody platform and may improve its ability to pursue development partnerships. Durable intellectual-property coverage can support pipeline differentiation and preserve strategic options as oncology assets advance.

Experienced Leadership Continuity

Returning an experienced former chief executive provides operational continuity during the search for permanent leadership. His prior company knowledge and healthcare background may help maintain strategic focus, while the former CEO’s continued corporate-development role preserves institutional expertise and partnering attention.

Bears Say

No Meaningful Revenue

The absence of meaningful revenue confirms that Purple Biotech remains pre-commercial and lacks a recurring operating base to fund research internally. Until an asset reaches commercialization or a partnership generates material income, financial performance will remain highly dependent on pipeline progress and external capital.

Persistent Large Losses

Persistent sizable losses show that research and development spending has not yet produced a stable commercial offset. Continued negative earnings can accelerate shareholder-capital consumption, constrain strategic flexibility, and make future performance increasingly dependent on successful clinical and partnering outcomes.

Ongoing Cash Burn And Capital Erosion

Negative operating and free cash flow indicate that the business is not self-funding, while the shrinking equity base reflects the cumulative effect of losses and possible dilution. This creates ongoing dependence on external funding and can limit the company’s ability to advance programs without financing risk.

Purple Biotech News

1YI0 FAQ

What was Purple Biotech’s price range in the past 12 months?
Purple Biotech lowest stock price was €0.28 and its highest was €0.38 in the past 12 months.
What is Purple Biotech’s market cap?
Purple Biotech’s market cap is €9.06M.
When is Purple Biotech’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Purple Biotech’s earnings last quarter?
Purple Biotech released its earnings results on Nov 17, 2026. The company reported -€0.546 earnings per share for the quarter, beating the consensus estimate of -€2.62 by €2.074.
Is Purple Biotech overvalued?
According to Wall Street analysts Purple Biotech’s price is currently Undervalued.
Does Purple Biotech pay dividends?
Purple Biotech does not currently pay dividends.
What is Purple Biotech’s EPS estimate?
Purple Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Purple Biotech have?
Purple Biotech has 1,620,982 shares outstanding.
What happened to Purple Biotech’s price movement after its last earnings report?
Purple Biotech reported an EPS of -€0.546 in its last earnings report, beating expectations of -€2.62. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Purple Biotech?
Currently, no hedge funds are holding shares in DE:1YI0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology